News

Apr 08, 2021 Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway

Mar 31, 2021 Headline test 2

Mar 31, 2021 Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

Mar 22, 2021 Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

Mar 11, 2021 Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

Feb 25, 2021 Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Feb 10, 2021 Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021

Feb 03, 2021 Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

Feb 02, 2021 Atossa Therapeutics' Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early

Jan 29, 2021 Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants

1 2 3 4 5 6 7 8 9 10

<< < > >>